These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases]. Alter M; Wittmann M; Völker B; Kapp A; Werfel T; Gutzmer R Hautarzt; 2009 Sep; 60(9):743-8. PubMed ID: 19151961 [TBL] [Abstract][Full Text] [Related]
9. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. Leuci S; Levine D; Zhang J; Razzaque Ahmed A G Ital Dermatol Venereol; 2009 Aug; 144(4):379-409. PubMed ID: 19755943 [TBL] [Abstract][Full Text] [Related]
10. Rituximab for autoimmune blistering diseases: recent studies, new insights. Lunardon L; Payne AS G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328 [TBL] [Abstract][Full Text] [Related]
11. [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins]. Mühlhoff C; Megahed M Hautarzt; 2007 Nov; 58(11):924-6. PubMed ID: 17952393 [No Abstract] [Full Text] [Related]
12. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Goebeler M; Herzog S; Bröcker EB; Zillikens D Br J Dermatol; 2003 Oct; 149(4):899-901. PubMed ID: 14616397 [No Abstract] [Full Text] [Related]
13. A single cycle of rituximab for the treatment of severe pemphigus. Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130 [TBL] [Abstract][Full Text] [Related]
14. Rituximab for pemphigus vulgaris. Joly P; D'Incan M; Musette P N Engl J Med; 2007 Feb; 356(5):521; author reply 521-2. PubMed ID: 17267915 [No Abstract] [Full Text] [Related]
16. [RITUXIMAB FOR THE TREATMENT OF PEMPHIGUS - A REVIEW OF RECENT STUDIES AND PERSONAL EXPERIENCE FROM THE RABIN MEDICAL CENTER AND THE SHEBA MEDICAL CENTER]. Mimouni D; Baum S Harefuah; 2020 Jan; 159(1):31-33. PubMed ID: 31930805 [TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402 [TBL] [Abstract][Full Text] [Related]
18. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Colliou N; Picard D; Caillot F; Calbo S; Le Corre S; Lim A; Lemercier B; Le Mauff B; Maho-Vaillant M; Jacquot S; Bedane C; Bernard P; Caux F; Prost C; Delaporte E; Doutre MS; Dreno B; Franck N; Ingen-Housz-Oro S; Chosidow O; Pauwels C; Picard C; Roujeau JC; Sigal M; Tancrede-Bohin E; Templier I; Eming R; Hertl M; D'Incan M; Joly P; Musette P Sci Transl Med; 2013 Mar; 5(175):175ra30. PubMed ID: 23467561 [TBL] [Abstract][Full Text] [Related]
19. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. El Tal AK; Posner MR; Spigelman Z; Ahmed AR J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351 [TBL] [Abstract][Full Text] [Related]